Ophthalmic Preparation Patents (Class 424/78.04)
  • Patent number: 10639274
    Abstract: A lubricant formulation of carbamoylethyl katira and a microwave assisted process for the preparation of the lubricant formulation of carbamoylethyl katira. The lubricant formulation of carbamoylethyl katira having antibacterial activity useful for eye lubricant based formulations, treatment of dry eye disease syndrome, etc.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: May 5, 2020
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Vikas Rana, Radhika Sharma, Sunil Kamboj, Kuldeep Singh, Sarasija Suresh
  • Patent number: 10617763
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a cryoprotectant. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 14, 2020
    Assignee: PRESBYOPIA THERAPIES, LLC
    Inventors: Gerald Horn, Lee Nordan
  • Patent number: 10595532
    Abstract: The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.
    Type: Grant
    Filed: August 6, 2018
    Date of Patent: March 24, 2020
    Assignee: FXS VENTURES, LLC
    Inventor: Francis X. Smith
  • Patent number: 10532026
    Abstract: The present invention is an aqueous solution which contains two types of methyl celluloses, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains a low viscosity around room temperature, but the composition is suddenly increased in the viscosity due to heat around the body temperature and has thixotropy even after gelation.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: January 14, 2020
    Assignee: WAKAMOTO PHARMACEUTICAL CO., LTD.
    Inventors: Takeshi Yamamura, Ayaka Yamamuro, Emi Izukura, Moto Kimura, Tomohiro Otsuka
  • Patent number: 10493155
    Abstract: The present invention relates to a heat-sterilized aqueous composition comprising a solubilized chitosan and glycerol. It also relates to a process of preparation of the same, as well as the use thereof, including compositions useful for the prevention and treatment of dry eye syndrome and arthritic diseases or disorders.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: December 3, 2019
    Assignee: LABORATOIRE MEDIDOM SA
    Inventors: Leila Yolanda Bossy, Alessandro Di Napoli
  • Patent number: 10451612
    Abstract: Aspects and embodiments of the instant disclosure provide a particle and/or intracellular organelle alignment agent for a particle analyzer used to analyze particles contained in a sample. An exemplary particle and/or intracellular organelle alignment agent includes an aqueous solution, a viscosity modifier, and/or a buffer.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: October 22, 2019
    Assignee: Iris International, Inc.
    Inventors: Gregory A. Farrell, Bart J. Wanders, Thomas H. Adams, Warren Groner, Xiaodong Zhao
  • Patent number: 10398707
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: September 3, 2019
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Patent number: 10130652
    Abstract: The present invention relates to the use as an anti-inflammatory of tamarind seed polysaccharide (TSP) and to anti-inflammatory compositions which contain it as active ingredient. Anti-inflammatory compositions containing TSP are particularly useful for topical administration in the treatment of inflammatory diseases of the skin and mucosa.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: November 20, 2018
    Assignee: INDENA S.P.A.
    Inventors: Andrea Giori, Sabrina Arpini, Stefano Togni
  • Patent number: 10064410
    Abstract: The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: September 4, 2018
    Assignee: FXS VENTURES, LLC
    Inventor: Francis X. Smith
  • Patent number: 10058615
    Abstract: The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: August 28, 2018
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Bastian Theisinger, Sonja Theisinger
  • Patent number: 9907750
    Abstract: The purpose of the present invention is to provide a technique for formulating a two-layer separation-type ophthalmic solution in which, during storage, an aqueous layer and an oil-containing layer containing squalane are separated from each other, wherein it is possible to homogeneously disperse the oil-containing layer in the aqueous layer while suppressing foaming by shaking the ophthalmic solution before administration, and the homogeneous dispersed state is maintained in a stable manner at least until administration. A two-layer separation-type ophthalmic solution containing squalane and water, wherein hyaluronic acid and/or a salt thereof and polyvinyl alcohol are contained in the ophthalmic solution and the polyvinyl alcohol content is set to 0.025 to 0.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: March 6, 2018
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventor: Shirou Sawa
  • Patent number: 9872927
    Abstract: The invention relates to a water-based biocompatible non-cytotoxic preparation for the selective staining of internal limiting membrane (ILM) and/or epiretinal membranes (ERM) in the human or animal eye, and to a kit containing said water-based preparation according to the invention.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: January 23, 2018
    Assignee: FLUORON GMBH
    Inventors: Christian Lingenfelder, Bastian Theisinger, Wilfried Hiebl, Nadine Hagedorn
  • Patent number: 9795560
    Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: October 24, 2017
    Assignee: Ocularis Pharma, LLC
    Inventor: Alan Meyer
  • Patent number: 9775846
    Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: October 3, 2017
    Assignee: Allergan, Inc.
    Inventor: Patrick M. Hughes
  • Patent number: 9765340
    Abstract: RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: September 19, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John M. Yanni, Jon E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • Patent number: 9707238
    Abstract: Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the cyclic lipid component can be encapsulated by the polymeric component. The present microparticles include oil-in-water emulsified microparticles. The subconjunctivally administered microparticles can be used to treat or to reduce at least one symptom of an ocular condition, such as glaucoma or age related macular degeneration.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: July 18, 2017
    Assignee: Allergan, Inc.
    Inventors: James Chang, Patrick Hughes, Chin-Ming Chang
  • Patent number: 9642360
    Abstract: Cationic antimicrobial polymers have been synthesized by a bulk addition polymerization of a nucleophilic agent comprising two tertiary amines and an electrophilic agent that comprises two leaving groups and an aromatic ring between the leaving groups. The reaction solvent for the polymerization is chosen to allow precipitation of the cationic polymer at the polymerization temperature, thereby limiting molecular weight. Quaternization and polymerization occur concurrently. The cationic polymers can be highly active against Gram-negative and Gram-positive microbes, and/or fungi. The cationic polymers can also be non-hemolytic and non-cytotoxic at the effective concentration against the microbes.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 9, 2017
    Assignees: International Business Machines Corporation, Agency For Science, Technology And Research
    Inventors: Julian M. W. Chan, James L. Hedrick, Robert J. Ono, Jye Yng Teo, Yi Yan Yang, Mu San Zhang
  • Patent number: 9636355
    Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: May 2, 2017
    Assignee: Theo Holdings, LLC
    Inventor: John M. Szabocsik
  • Patent number: 9585394
    Abstract: The present invention relates to improved ophthalmic solutions that employ select B vitamins; pyridoxine and its salts; and thiamine and its salts in order to more effectively preserve solutions and to reduce the degree to which cationic preservatives will deposit on contact lenses. Ophthalmic solutions are here understood to include contact lens treatment solutions, such as cleaners, soaking solutions, conditioning solutions and lens storage solutions, as well as wetting solutions and in-eye solutions for treatment of eye conditions.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: March 7, 2017
    Assignee: FXS VENTURES, LLC
    Inventor: Francis X. Smith
  • Patent number: 9572859
    Abstract: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of a composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: February 21, 2017
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Orest Olejnik, Scott M. Whitcup, James A. Burke
  • Patent number: 9480696
    Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: November 1, 2016
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: James J. Collins, Kyle R. Allison, Mark P. Brynildsen
  • Patent number: 9453220
    Abstract: RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: September 27, 2016
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: John M. Yanni, John E. Chatterton, Daniel A. Gamache, Steven T. Miller
  • Patent number: 9452177
    Abstract: The present invention relates to compounds and methods for reducing intraocular pressure and treating ocular hypertension in a subject.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: September 27, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Galina D. Kutuzova, Paul L. Kaufman, B'Ann True Gabelt
  • Patent number: 9427737
    Abstract: Oil compositions and methods for use in droplet formation or in spacing of droplets are disclosed. The oil compositions may include a combination, such as a silicone oil and a fluorine-containing compound. The droplets can contain analytes (e.g., nucleic acids) and may be used for molecular reactions (e.g., digital PCR) and detection.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: August 30, 2016
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Nicholas Jack Heredia, Anthony J. Makarewicz, Jr.
  • Patent number: 9421184
    Abstract: The present invention relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof to a patient in need of such a treatment. The invention further relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof in combination with one or more additional anti-inflammatory active agents to a patient in need of such a treatment.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: August 23, 2016
    Assignee: ITALFARMACO S.P.A.
    Inventors: Valentina Saccone, Silvia Consalvi, Pier Lorenzo Puri, Paolo Mascagni
  • Patent number: 9393243
    Abstract: Embodiments of the invention provide pharmaceutical compositions of ciprofloxacin formulated for topical application to a body surface and for having at least localized antibacterial activity. In some embodiments, the compositions are further formulated for localized anti-inflammatory activity, anti-fungal activity, anti-viral activity, or combinations thereof. Such compositions possess a therapeutically effective amount of a non-betaine form ciprofloxacin (e.g., ciprofloxacin hydrochloride monohydrate); one of a pH adjusting agent and a preservative; water; and a pH from about 5.5 to about 10. In some embodiments, such compositions may be free or free of added skin permeation enhancer and/or contain a betaine form ciprofloxacin.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: July 19, 2016
    Inventors: Nilesh Parikh, William Crawford Hite
  • Patent number: 9387164
    Abstract: The present invention relates to ophthalmic preparations in the form of eyedrops based on BDNF (Brain-Derived Neurotrophic Factor). Said preparations can be administered topically to the intact eye surface, and are useful in the prevention and treatment of neurodegenerative disorders of the retina, optic nerve, lateral geniculate body and visual cortex, in order to prevent reduction of visual capacity and restore the normal visual function.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: July 12, 2016
    Assignee: HMFRA HUNGARY LIMITED LIABILITY COMPANY
    Inventors: Luciano Domenici, Luca Giovannini, Marco Sanso′
  • Patent number: 9351990
    Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: May 31, 2016
    Assignee: Theo Holdings, LLC
    Inventor: John M. Szabocsik
  • Patent number: 9351991
    Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: May 31, 2016
    Assignee: Theo Holdings, LLC
    Inventor: John M. Szabocsik
  • Patent number: 9345714
    Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: May 24, 2016
    Assignee: Alcon Pharmaceuticals Ltd.
    Inventors: G. Michael Wall, Peter J. Conroy
  • Patent number: 9259429
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: February 16, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Patent number: 9241900
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: January 26, 2016
    Assignee: NOVALIQ GMBH
    Inventor: Clive G. Wilson
  • Patent number: 9181517
    Abstract: A composition for cleaning contact lenses and producing a removable visible discharge comprising: polyvinyl-alcohol; povidone; and an isotonic contact solution.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: November 10, 2015
    Inventor: Satoshi Takeuchi
  • Patent number: 9149555
    Abstract: The present invention relates to a lens care solution having 0.001 to about 5 weight percent of a low molecular weight amine of the general formula: where R1, R2, R3 and R4 are —H or low molecular weight radicals, and R5 is a low molecular weight radical, or salt thereof; an effective amount of a tonicity agent; and the balance water.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: October 6, 2015
    Assignee: FXS Ventures, LLC
    Inventor: Francis X. Smith
  • Patent number: 9138481
    Abstract: The present invention is directed to cellulosic gel compositions having improved viscosity stability through the exclusion of particular antioxidants and/or the exclusion of chemical entities that tend to produce free radicals. Preferably, the composition is an ophthalmic cellulosic gel composition that is suitable as a multi-dose composition.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: September 22, 2015
    Assignee: Alcon Research, Ltd.
    Inventors: Gemma Torrella, Guadalupe Almera, Jordi Garcés
  • Patent number: 9119827
    Abstract: Disclosed is an ophthalmic composition which is characterized by containing (A) a vitamin A, (B) a polyoxyethylene polyoxypropylene glycol, and (C) an oil component that is selected from the group consisting of castor oil, soybean oil, sesame oil, peanut oil, olive oil, almond oil, wheat germ oil, corn oil, rapeseed oil, sunflower oil, purified lanolin and gel hydrocarbon.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: September 1, 2015
    Assignee: LION CORPORATION
    Inventors: Akito Odaka, Chieko Inoue, Manabu Hattori, Nobuhito Tabuchi
  • Patent number: 9089560
    Abstract: The invention provides methods, compositions, and kits containing phentolamine for improving visual performance. In particular, the invention provides improvement in visual performance, such as improvement in visual acuity, by daily ophthalmic administration of a phentolamine solution to an eye of a patient at or near the bedtime of the patient for an extended duration while minimizing the occurrence of adverse side effects, such as eye redness during the patient's waking hours.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: July 28, 2015
    Assignee: Ocularis Pharma, LLC
    Inventor: Alan Meyer
  • Patent number: 9044484
    Abstract: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate and a low concentration of benzalkonium chloride.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: June 2, 2015
    Assignee: Alcon Research, Ltd.
    Inventor: Bhagwati P. Kabra
  • Publication number: 20150139932
    Abstract: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 21, 2015
    Inventors: C. Michael SAMSON, Bo LIANG, Joseph A. CAPRIOTTI
  • Patent number: 9017716
    Abstract: The present invention is directed to an ophthalmic lens integrally formed with a hydrogel, the hydrogel including a copolymer obtained from a composition containing (A) an ionic compound including a cation having a polymerizable functional group, and a fluorine-containing anion (hereinafter, referred to as (A) ionic compound), and (B) a hydrophilic compound having a polymerizable functional group.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: April 28, 2015
    Assignee: Menicon Co., Ltd.
    Inventor: Kohsuke Satake
  • Patent number: 9005596
    Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: April 14, 2015
    Assignee: Eyeon Particle Sciences LLC
    Inventors: Eugene Rex Cooper, David Maxwell Kleinman, Andrew Loxley, Mark Mitchnick
  • Patent number: 8979809
    Abstract: A method for optimizing pupil size in individuals suffering from excessive pupillary dilation in dim light as well as through medication is disclosed. Alpha 1 antagonist is applied in an eye drop formulation to the eye, resulting in reduced pupil size in dim light, but less reduction in pupil size in bright light.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: March 17, 2015
    Assignee: Ocularis Pharma, LLC
    Inventor: Gerald Horn
  • Patent number: 8969307
    Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Patent number: 8956600
    Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
    Type: Grant
    Filed: August 10, 2009
    Date of Patent: February 17, 2015
    Assignees: Taiwan Liposome Co. Ltd., TLC Biopharmaceuticals, Inc.
    Inventors: Sheue-Fang Shih, Po-Chun Chang, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
  • Patent number: 8921337
    Abstract: The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: December 30, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: Masood A. Chowhan, Malay Ghosh, Bahram Asgharian, Wesley Wehsin Han
  • Patent number: 8920841
    Abstract: A polymer system useful for in vivo delivery of a therapeutic agent is provided. The polymer system comprises a biocompatible biodegradable polymeric backbone that is capable of a reversible stimuli-induced transition from liquid to gel.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: December 30, 2014
    Inventors: Heather Sheardown, Scott Fitzpatrick, M.A. Jafar Mazumder
  • Publication number: 20140377210
    Abstract: The invention provides artificial tear compositions comprising one or more nonionic surfactants with one or more non-Newtonian viscosity enhancing excipients.
    Type: Application
    Filed: September 24, 2013
    Publication date: December 25, 2014
    Applicant: GNT, LLC
    Inventor: Gerald Horn
  • Publication number: 20140369951
    Abstract: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.
    Type: Application
    Filed: June 26, 2014
    Publication date: December 18, 2014
    Applicant: CLS Pharmaceuticals, Inc.
    Inventors: C. Michael SAMSON, Bo LIANG, Joseph A. CAPRIOTTI
  • Patent number: 8912166
    Abstract: An ophthalmic preparation and method, usable to treat conjunctivochalasis. The ophthalmic preparation comprises an aqueous solution of glycerol. The preparation may also include additional components including high molecular weight polymers for viscosity control and pharmacologically active substances. The method includes administering an ophthalmic preparation including an aqueous solution of glycerol to a patient.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: December 16, 2014
    Assignee: Resdevco Research and Development Co. Ltd.
    Inventor: Shabtay Dikstein
  • Patent number: 8906861
    Abstract: A composition is described herein comprising cyclosporin A, polysorbate 80, a polyoxyethylene stearate, and an oil; wherein the composition is an emulsion which is ophthalmically acceptable. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: December 9, 2014
    Assignee: Allergan, Inc.
    Inventors: Walter L. Tien, Richard S. Graham, James N. Chang